Author： Nakata Kensei Sakata Koh-ichi Someya Masanori Miura Katsutoshi Hayashi Junichi Hori Masakazu Takagi Masaru Himi Tetsuo Kondo Atsushi Hareyama Masato
Publisher： Oxford University Press
ISSN： 0449-3060
Source： Journal of Radiation Research, Vol.54, Iss.4, 2013-07, pp. : 679-683
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
This study investigated the maximum tolerated dose (MTD) of S-1 with concurrent radiotherapy in patients with head and neck cancer, based on the frequency of dose-limiting toxicities (DLT). S-1 was administered orally at escalating doses from 40 mg/m2 b.i.d. on the days of delivering radiotherapy, which was given at a total dose of 6470 Gy in 3235 fractions over 67 weeks. A total of 12 patients (3 patients at 40 mg/m2, 6 patients at 60 mg/m2, and 3 patients at 80 mg/m2) were enrolled in this trial. At the dose of 80 mg/m2, two of the three patients developed DLT (Grade 3 anorexia and rhabdomyolysis) due to S-1, so the MTD was determined to be 80 mg/m2. Among the 12 enrolled patients, 9 (75) showed a complete response and 3 (25) showed a partial response. The overall response rate was 100. The recommended dose of S-1 with concurrent radiotherapy is 60 mg/m2.
Related content
By Budach V. Becker E.-T. Boehmer D. Badakhshi H. Jahn U. Wernecke K.-D. Stromberger C.
Strahlentherapie und Onkologie, Vol. 190, Iss. 3, 2014-03 ,pp. :
Access to resources
Recommend
By Picchio M. Kirienko M. Mapelli P. Dell’Oca I. Villa E. Gallivanone F. Gianolli L. Messa C. Castiglioni I.
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, Iss. 1, 2014-01 ,pp. :